These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 34689796)
41. Quantifying and preventing Plasmodium vivax recurrences in primaquine-untreated pregnant women: An observational and modeling study in Brazil. Corder RM; de Lima ACP; Khoury DS; Docken SS; Davenport MP; Ferreira MU PLoS Negl Trop Dis; 2020 Jul; 14(7):e0008526. PubMed ID: 32735631 [TBL] [Abstract][Full Text] [Related]
42. CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study. Brasil LW; Rodrigues-Soares F; Santoro AB; Almeida ACG; Kühn A; Ramasawmy R; Lacerda MVG; Monteiro WM; Suarez-Kurtz G Malar J; 2018 Feb; 17(1):57. PubMed ID: 29390987 [TBL] [Abstract][Full Text] [Related]
43. Monitoring of clinical efficacy and in vitro sensitivity of Plasmodium vivax to chloroquine in area along Thai Myanmar border during 2009-2010. Muhamad P; Ruengweerayut R; Chacharoenkul W; Rungsihirunrat K; Na-Bangchang K Malar J; 2011 Feb; 10():44. PubMed ID: 21324161 [TBL] [Abstract][Full Text] [Related]
44. Chloroquine-Primaquine versus Chloroquine Alone to Treat Vivax Malaria in Afghanistan: An Open Randomized Superiority Trial. Awab GR; Imwong M; Bancone G; Jeeyapant A; Day NPJ; White NJ; Woodrow CJ Am J Trop Med Hyg; 2017 Dec; 97(6):1782-1787. PubMed ID: 29141719 [TBL] [Abstract][Full Text] [Related]
45. Recurrent Plasmodium vivax malaria due to dose-dependent primaquine resistance: a case report. Kristensen KL; Dragsted UB Scand J Infect Dis; 2014 Jan; 46(1):63-5. PubMed ID: 23957539 [TBL] [Abstract][Full Text] [Related]
46. Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse therapy. Goller JL; Jolley D; Ringwald P; Biggs BA Am J Trop Med Hyg; 2007 Feb; 76(2):203-7. PubMed ID: 17297026 [TBL] [Abstract][Full Text] [Related]
47. Directly observed therapy with primaquine to reduce the recurrence rate of plasmodium vivax infection along the Thai-Myanmar border. Maneeboonyang W; Lawpoolsri S; Puangsa-Art S; Yimsamran S; Thanyavanich N; Wuthisen P; Prommongkol S; Chaimongkul W; Rukmanee P; Rukmanee N; Chavez IF; Buchachart K; Krudsood S; Singhasivanon P Southeast Asian J Trop Med Public Health; 2011 Jan; 42(1):9-18. PubMed ID: 21323159 [TBL] [Abstract][Full Text] [Related]
48. Plasmodium vivax morbidity after radical cure: A cohort study in Central Vietnam. Pham TV; Nguyen HV; Aguirre AR; Nguyen VV; A Cleves M; Nguyen XX; Nguyen TT; Tran DT; Le HX; Hens N; Rosanas-Urgell A; D'Alessandro U; Speybroeck N; Erhart A PLoS Med; 2019 May; 16(5):e1002784. PubMed ID: 31100064 [TBL] [Abstract][Full Text] [Related]
49. High-dose primaquine regimens against relapse of Plasmodium vivax malaria. Krudsood S; Tangpukdee N; Wilairatana P; Phophak N; Baird JK; Brittenham GM; Looareesuwan S Am J Trop Med Hyg; 2008 May; 78(5):736-40. PubMed ID: 18458306 [TBL] [Abstract][Full Text] [Related]
50. A clinical tool to predict Plasmodium vivax recurrence in Malaysia. Mat Ariffin N; Islahudin F; Kumolosasi E; Makmor-Bakry M BMC Infect Dis; 2017 Dec; 17(1):759. PubMed ID: 29216842 [TBL] [Abstract][Full Text] [Related]
52. Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report. He X; Pan M; Zeng W; Zou C; Pi L; Qin Y; Zhao L; Qin P; Lu Y; Baird JK; Huang Y; Cui L; Yang Z BMC Infect Dis; 2019 Aug; 19(1):704. PubMed ID: 31399061 [TBL] [Abstract][Full Text] [Related]
54. Suppressive chemoprophylaxis invites avoidable risk of serious illness caused by Plasmodium vivax malaria. Baird JK Travel Med Infect Dis; 2013; 11(1):60-5. PubMed ID: 23454204 [TBL] [Abstract][Full Text] [Related]
55. Development of resistance to chloroquine by Plasmodium vivax in Myanmar. Marlar-Than ; Myat-Phone-Kyaw ; Aye-Yu-Soe ; Khaing-Khaing-Gyi ; Ma-Sabai ; Myint-Oo Trans R Soc Trop Med Hyg; 1995; 89(3):307-8. PubMed ID: 7660445 [TBL] [Abstract][Full Text] [Related]
56. Efficacy of Chloroquine and Primaquine for the Treatment of Uncomplicated Plasmodium vivax Malaria in Cruzeiro do Sul, Brazil. Negreiros S; Farias S; Viana GM; Okoth SA; Chenet SM; de Souza TM; Marchesini P; Udhayakumar V; Povoa MM; Santelli AC; de Oliveira AM Am J Trop Med Hyg; 2016 Nov; 95(5):1061-1068. PubMed ID: 27549633 [TBL] [Abstract][Full Text] [Related]
57. Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. Llanos-Cuentas A; Lacerda MVG; Hien TT; Vélez ID; Namaik-Larp C; Chu CS; Villegas MF; Val F; Monteiro WM; Brito MAM; Costa MRF; Chuquiyauri R; Casapía M; Nguyen CH; Aruachan S; Papwijitsil R; Nosten FH; Bancone G; Angus B; Duparc S; Craig G; Rousell VM; Jones SW; Hardaker E; Clover DD; Kendall L; Mohamed K; Koh GCKW; Wilches VM; Breton JJ; Green JA N Engl J Med; 2019 Jan; 380(3):229-241. PubMed ID: 30650326 [TBL] [Abstract][Full Text] [Related]
58. Plasmodium vivax malaria relapses at a travel medicine centre in Rio de Janeiro, a non-endemic area in Brazil. Pedro RS; Guaraldo L; Campos DP; Costa AP; Daniel-Ribeiro CT; Brasil P Malar J; 2012 Jul; 11():245. PubMed ID: 22839416 [TBL] [Abstract][Full Text] [Related]
59. Effects of liver-stage clearance by Primaquine on gametocyte carriage of Plasmodium vivax and P. falciparum. Wampfler R; Hofmann NE; Karl S; Betuela I; Kinboro B; Lorry L; Silkey M; Robinson LJ; Mueller I; Felger I PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005753. PubMed ID: 28732068 [TBL] [Abstract][Full Text] [Related]
60. Compliance to recommendations for the management of curative treatment of Plasmodium vivax/ovale infections. Faucher JF; Bellanger AP; Shaniya N; Hustache-Mathieu L; Hoen B; Chirouze C Med Mal Infect; 2014 Aug; 44(8):387-9. PubMed ID: 25015307 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]